Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H1 2017
- Pages: 486
- Published: May 2017
- Report Code: GMDHC9375IDB
Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H1 2017’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
– The report reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics and enlists all their major and minor projects
– The report assesses Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
AbbVie Inc
Altor BioScience Corp
arGEN-X BV
Ariad Pharmaceuticals Inc
Array BioPharma Inc
Astex Pharmaceuticals Inc
Atara Biotherapeutics Inc
Bio-Path Holdings Inc
BioLineRx Ltd
BioSight Ltd
BLR Bio LLC
Boston Biomedical Inc
Bristol-Myers Squibb Company
Cantargia AB
Celgene Corp
Cellectar Biosciences Inc
Cellectis SA
Cielo Therapeutics Inc
Constellation Pharmaceuticals Inc
Daiichi Sankyo Company Ltd
Deciphera Pharmaceuticals LLC
Eisai Co Ltd
EpiZyme Inc
Galena Biopharma Inc
Gamida Cell Ltd
GlaxoSmithKline Plc
GlycoMimetics Inc
Hovione FarmaCiencia SA
Hybrigenics SA
Ilyang Pharmaceutical Co Ltd
Immune Pharmaceuticals Inc
Incyte Corp
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
JW Pharmaceutical Corp
Karyopharm Therapeutics Inc
Lixte Biotechnology Holdings Inc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
Natco Pharma Ltd
Novartis AG
OncoImmune Inc
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Oribase Pharma
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Phylogica Ltd
Selvita SA
Shenogen Pharma Group Ltd
SignalChem Lifesciences Corp
Stemline Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Synactix Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
TRACON Pharmaceuticals Inc
Tragara Pharmaceuticals Inc
VioQuest Pharmaceuticals Inc
Xencor Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.